LEXX – lexaria bioscience corp. (US:NASDAQ)
Stock Stats
News
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm [Yahoo! Finance]
Lexaria Releases Annual Letter from the CEO
Lexaria Bioscience Corp. (NASDAQ: LEXX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00. They now have a "buy" rating on the stock.
Lexaria Bioscience files for $50M mixed securities shelf [Seeking Alpha]
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Form 8-K Lexaria Bioscience Corp. For: Feb 05
Form 424B5 Lexaria Bioscience Corp.
Form EFFECT Lexaria Bioscience Corp.
Form S-3 Lexaria Bioscience Corp.
Form 3 Lexaria Bioscience Corp. For: Jan 14 Filed by: Bhullar Baljinder
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.